Characteristic and quantifiable COVID-19-like abnormalities in CT- and PET/CT-imaged lungs of SARS-CoV-2-infected crab-eating macaques (Macaca fascicularis)
Finch, C. L.; Crozier, I.; Lee, J. H.; Byrum, R.; Cooper, T. K.; Liang, J.; Sharer, K.; Solomon, J.; Sayre, P. J.; Kocher, G.; Bartos, C.; Aiosa, N. M.; Castro, M.; Larson, P. A.; Adams, R.; Beitzel, B.; Di Paola, N.; Kugelman, J. R.; Kurtz, J. R.; Burdette, T.; Nason, M. C.; Feuerstein, I. M.; Palacios, G.; St. Claire, M. C.; Lackemeyer, M. G.; Johnson, R. F.; Braun, K. M.; Ramuta, M. D.; Wada, J.; Schmaljohn, C. S.; Friedrich, T. C.; O'Connor, D. H.; Kuhn, J. H.
Show abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing an exponentially increasing number of coronavirus disease 19 (COVID-19) cases globally. Prioritization of medical countermeasures for evaluation in randomized clinical trials is critically hindered by the lack of COVID-19 animal models that enable accurate, quantifiable, and reproducible measurement of COVID-19 pulmonary disease free from observer bias. We first used serial computed tomography (CT) to demonstrate that bilateral intrabronchial instillation of SARS-CoV-2 into crab-eating macaques (Macaca fascicularis) results in mild-to-moderate lung abnormalities qualitatively characteristic of subclinical or mild-to-moderate COVID-19 (e.g., ground-glass opacities with or without reticulation, paving, or alveolar consolidation, peri-bronchial thickening, linear opacities) at typical locations (peripheral>central, posterior and dependent, bilateral, multi-lobar). We then used positron emission tomography (PET) analysis to demonstrate increased FDG uptake in the CT-defined lung abnormalities and regional lymph nodes. PET/CT imaging findings appeared in all macaques as early as 2 days post-exposure, variably progressed, and subsequently resolved by 6-12 days post-exposure. Finally, we applied operator-independent, semi-automatic quantification of the volume and radiodensity of CT abnormalities as a possible primary endpoint for immediate and objective efficacy testing of candidate medical countermeasures.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2 93%
- Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters 93%
- A Single Dose of Inactivated Influenza Virus Vaccine Expressing COBRA Hemagglutinin Elicits Broadly-Reactive and Long-Lasting Protection 92%
Similar papers in this journal
- Murine Alveolar Macrophages Rapidly Accumulate Intranasally Administered SARS-CoV-2 Spike Protein leading to Neutrophil Recruitment and Damage 92%
- SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous SARS-CoV2 variants of concern 92%
- Immunogenicity and safety of a live-attenuated SARS-CoV-2 vaccine candidate based on multiple attenuation mechanisms 92%
Similar papers in this journal
- SARS-CoV-2 causes brain inflammation and induces Lewy body formation in macaques 95%
- The post-acute phase of SARS-CoV-2 infection in two macaques species is associated with signs of ongoing virus replication and pathology in pulmonary and extrapulmonary tissues 94%
- TMPRSS2 is essential for SARS-CoV-2 Beta and Omicron infection 93%
Similar papers in this journal
- Long-term persistence of viral RNA and inflammation in the CNS of macaques exposed to aerosolized Venezuelan equine encephalitis virus. 95%
- IL-10 suppresses T cell expansion while promoting tissue-resident memory cell formation during SARS-CoV-2 infection in rhesus macaques 95%
- K18-hACE2 mice develop respiratory disease resembling severe COVID-19 94%
Similar papers in this journal
- Monitoring SARS-CoV-2 infection using a double reporter-expressing virus 94%
- Bi-reporter vaccinia virus for tracking viral infections in vitro and in vivo 93%
- Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV 2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.